Mary Collins

USPTO Granted Patents = 35 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 7)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 5.7

ph-index = 17

Forward Citations = 1,649(Granted Patents)

Location History:

Watertown, MA (US) (1988)
Natick, MA (US) (1988 - 2012)

Company Filing History:

23 out of 389

Genetics Institute, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Johns Hopkins University

patents

8. 1 out of 28

Cambridge Antibody Technology Limited

patents

9. 2 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 1988-2012

Loading Chart...

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8143385 - Nucleic acids coding for antibodies against human IL-21 receptor and uses therefor (2012-03-27),

2. 8088905 - Nucleic acids encoding antibodies against PD-1 (2012-01-03),

3. 7910105 - Methods for treating and preventing fibrosis (2011-03-22),

4. 7731946 - [object Object] (2010-06-08),

5. 7674591 - Methods of using antibodies to human IL-13bc for inhibiting IL-13 binding (2010-03-09),

6. 7666421 - Methods of treatment of autoimmune diseases using humanized immunoglobulin reactive with B7-2 (2010-02-23),

7. 7618632 - Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies (2009-11-17),

8. 7553487 - Method and compositions for treating asthma (2009-06-30),

9. 7531175 - Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules (2009-05-12),

10. 7521051 - Methods of upmodulating adaptive immune response using anti-PD-1 antibodies (2009-04-21),

11. 7507706 - Cytokine receptor chain (2009-03-24),

12. 7495085 - Antibodies against human or mouse IL-21 receptor (2009-02-24),

13. 7488802 - Antibodies against PD-1 (2009-02-10),

14. 7314623 - Methods and compositions for modulating T helper (Th) cell development and function (2008-01-01),

15. 7282206 - Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains (2007-10-16),

Certainly! Here is the article about inventor Mary Collins:

Title: The Innovative Work of Mary Collins in the Field of Immunotherapy

Introduction:

Mary Collins, a pioneering inventor based in Natick, MA (US), has made significant contributions to the field of immunotherapy with her groundbreaking inventions and patents.

Latest Patents:

Mary Collins' latest patents include:

1. "Nucleic acids coding for antibodies against human IL-21 receptor and uses therefor": Providing human antibodies that specifically bind to the human interleukin-21 receptor (IL-21R), acting as antagonists to modulate immune responses for treating various disorders.

2. "Nucleic acids encoding antibodies against PD-1": Offering antibodies that act as agonists and/or antagonists of PD-1, affecting immune responses and aiding in the treatment of autoimmune diseases and cancer.

Career Highlights:

Mary Collins has an impressive portfolio of 35 patents, showcasing her expertise in developing innovative solutions for immune system disorders. She has worked at Genetics Institute, Inc. and Wyeth, where she honed her skills and knowledge in the field.

Collaborations:

Throughout her career, Mary Collins has collaborated with esteemed professionals in the industry, including coworkers like Matthew James Whitters and Clive R Wood. These collaborations have led to the creation of impactful inventions with the potential to revolutionize the treatment of various diseases.

Conclusion:

Mary Collins' dedication to advancing immunotherapy through her inventive creations has established her as a leading figure in the field. Her patents serve as a testament to her commitment to improving healthcare and making a positive impact on the lives of many.

This text is generated by artificial intelligence and may not be accurate.